AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27893654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine D
Number of subjects: 4000
Study 24789668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (low-intensity) for 18 months
Number of subjects: 213
Study 24789668 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite lifestyle change (weight reduction of at least 5% and improvement in exercise capacity of at least 10%)
Number of subjects: 213
Study 21895621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius plus fructo-oligosaccharide (synbiotic)
Number of subjects: 60
Study 21895621 — intervention group
Group type: COMPARATOR
Intervention: Fructo-oligosaccharide (prebiotic)
Number of subjects: 60
Study 20613470 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (CePROP)
Number of subjects: 45
Study 20613470 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0, 2, and 4 ng/ml)
Number of subjects: 45
Study 18806050 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) anesthesia
Number of subjects: 72
Study 18806050 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-opioid anesthesia
Number of subjects: 72
Study 16253965 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist administration
Number of subjects: 1317
Study 16253965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyst cycles
Number of subjects: 1317
Study 16253965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cysts
Number of subjects: 1317
Study 16253965 — intervention group
Group type: COMPARATOR
Intervention: Cyst aspiration
Number of subjects: 1317
Study 14508155 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic use and infection control practices
Number of subjects: 0
Study 14508155 — intervention group
Group type: COMPARATOR
Intervention: Third-generation cephalosporins, carbapenems, and fluoroquinolones
Number of subjects: 0
Study 14508155 — intervention group
Group type: COMPARATOR
Intervention: Extended-spectrum beta-lactamases
Number of subjects: 0
Study 14508155 — intervention group
Group type: COMPARATOR
Intervention: Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia
Number of subjects: 0
Study 10685301 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone-lying position
Number of subjects: 48
Study 10685301 — intervention group
Group type: COMPARATOR
Intervention: Supine-lying position
Number of subjects: 48
Study 7793587 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) - parenteral cefotaxime, oral and enteral polymyxin E, tobramycin, and amphotericin B
Number of subjects: 135
Study 7793587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 7793587 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 135
Study 1726639 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetohydroxamic acid (AHA)
Number of subjects: 94
Study 1726639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 6992824 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study 6992824 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 6992824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30261171 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with bonding difficulties
Number of subjects: 75
Study 30261171 — intervention group
Group type: COMPARATOR
Intervention: Healthy mothers
Number of subjects: 75
Study 30261171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 28928556 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia with isoflurane (Group I)
Number of subjects: 60
Study 28928556 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol (Group II)
Number of subjects: 60
Study 25765348 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% minoxidil topical foam (5% MTF)
Number of subjects: 70
Study 25765348 — intervention group
Group type: COMPARATOR
Intervention: Placebo foam (plaTF)
Number of subjects: 70
Study 23764350 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 0.25 mg
Number of subjects: 297
Study 23764350 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 0.5 mg
Number of subjects: 297
Study 23764350 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 1.25 mg
Number of subjects: 297
Study 23764350 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 2 mg
Number of subjects: 297
Study 23764350 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 10 mg
Number of subjects: 297
Study 23764350 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) for 6 months
Number of subjects: 297
Study 23764350 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) for 3 months
Number of subjects: 297
Study 21187210 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions (3 maximal voluntary contractions, 25% MVC held to task failure, 25% MVC held for 2 minutes)
Number of subjects: 15
Study 21187210 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions
Number of subjects: 15
Study 19269254 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 64
Study 19269254 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression (within 48 h of stroke onset)
Number of subjects: 64
Study 19269254 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 64
Study 16900227 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance and resistance exercise plus nutritional counseling (EN)
Number of subjects: 12
Study 16900227 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling only (N)
Number of subjects: 12
Study 15581196 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (1 mg/daily)
Number of subjects: 60
Study 15581196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11722323 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment (stable dose)
Number of subjects: 74
Study 11722323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 9394975 — intervention group
Group type: EXPERIMENTAL
Intervention: Scratch-Monitor (SM) device
Number of subjects: 43
Study 9394975 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study 7651920 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with antiviral drugs
Number of subjects: 42
Study 2956372 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 40
Study 2956372 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 40
Study 2956372 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem vs Propranolol
Number of subjects: 40
Study 31584780 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion (halobetasol propionate 0.01% and tazarotene 0.045%)
Number of subjects: 62
Study 31584780 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 62
Study 28522311 — intervention group
Group type: EXPERIMENTAL
Intervention: Second appointment with fixed date and time (intervention)
Number of subjects: 26054
Study 28522311 — intervention group
Group type: COMPARATOR
Intervention: Invitation letter with a telephone number to book a new appointment (control)
Number of subjects: 26054
Study 26141044 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable acrylic plates
Number of subjects: 65
Study 24169346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib 360 mg BID with erlotinib for extensive metabolisers (EMs)
Number of subjects: 25
Study 24169346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib 240 mg BID with erlotinib for poor metabolisers (PMs)
Number of subjects: 25
Study 24169346 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to tivantinib and/or erlotinib (>20%, any grade)
Number of subjects: 25
Study 24169346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics profile of tivantinib
Number of subjects: 25
Study 22087066 — intervention group
Group type: EXPERIMENTAL
Intervention: Calligraphy therapy (intensive calligraphy training for eight weeks)
Number of subjects: 31
Study 22087066 — intervention group
Group type: COMPARATOR
Intervention: No calligraphy treatment (control group)
Number of subjects: 31
Study 18724864 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical mechanical periodontal treatment in the second trimester of pregnancy
Number of subjects: 0
Study 18724864 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16413592 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent live‐attenuated influenza virus vaccine (LAIV, FluMist)
Number of subjects: 56
Study 15477795 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs with renoprotective properties; specific types include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium antagonists, beta-blockers, and diuretics; dosage and duration not specified.
Number of subjects: 0
Study 15477795 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; control group not specified.
Number of subjects: 0
Study 11229849 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate vaccines (low, medium, high doses)
Number of subjects: 154
Study 11229849 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate vaccines
Number of subjects: 154
Study 11229849 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant
Number of subjects: 154
Study 11229849 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 154
Study 11229849 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected children
Number of subjects: 154
Study 9308620 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dextran-70 (HSD)
Number of subjects: 1233
Study 9308620 — intervention group
Group type: COMPARATOR
Intervention: 7.5% saline (HS)
Number of subjects: 1233
Study 8483785 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoxygenation (FiO2 = 1.0) via snug face mask for three minutes prior to lumbar puncture
Number of subjects: 21
Study 8483785 — intervention group
Group type: COMPARATOR
Intervention: Room air (control group)
Number of subjects: 21
Study 3324618 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/48 hours) + dipyridamole (300 mg/day)
Number of subjects: 243
Study 3324618 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (400 mg/day)
Number of subjects: 243
Study 29417365 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrition services and education at five visits and one phone call between delivery and 6 months postpartum.
Number of subjects: 53
Study 29417365 — intervention group
Group type: COMPARATOR
Intervention: Standard WIC services.
Number of subjects: 53
Study 29417365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control).
Number of subjects: 53
Study 27329124 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Number of subjects: 659
Study 27329124 — intervention group
Group type: COMPARATOR
Intervention: CHOP-14 arm of JCOG9801
Number of subjects: 659
Study 24001364 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered cognitive behavioural therapy (CBT) for insomnia over 6 weeks
Number of subjects: 118
Study 24001364 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 118
Study 21986705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU per month, equivalent to 2000 IU per day)
Number of subjects: 37
Study 21986705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 21986705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 37
Study 20840399 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Simulator (ICS)
Number of subjects: 58
Study 20840399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ICS access)
Number of subjects: 58
Study 18580407 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial (EX): 60‐min stationary cycle exercise (50% peak oxygen uptake) followed by 30‐min rest
Number of subjects: 8
Study 18580407 — intervention group
Group type: COMPARATOR
Intervention: Control trial (CON): 90‐min rest
Number of subjects: 8
Study 16152839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb and Sanchi Powder (RSP) - 3g of rhubarb and 2g of Sanchi Powder orally, 3-4 times daily
Number of subjects: 60
Study 16152839 — intervention group
Group type: COMPARATOR
Intervention: Dicynonum - 2g intravenously
Number of subjects: 60
Study 12629246 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 82
Study 12629246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 11682582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 g of protein x kg(‐1) x day(‐1)
Number of subjects: 11
Study 11682582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g of protein x kg(‐1) x day(‐1)
Number of subjects: 11
Study 11682582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00 g of protein x kg(‐1) x day(‐1)
Number of subjects: 11
Study 9453274 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate
Number of subjects: 63
Study 9453274 — intervention group
Group type: COMPARATOR
Intervention: Carob (placebo)
Number of subjects: 63
Study 7930384 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 110
Study 7930384 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched)
Number of subjects: 110
Study 2975291 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg
Number of subjects: 16
Study 2975291 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg
Number of subjects: 16
Study 2975291 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg
Number of subjects: 16
Study 2975291 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 20 mg
Number of subjects: 16
Study 2975291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31342057 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient parenteral antimicrobial therapy plus buprenorphine treatment
Number of subjects: 0
Study 31342057 — intervention group
Group type: COMPARATOR
Intervention: Usual care (inpatient intravenous antibiotic completion)
Number of subjects: 0
Study 29099925 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy (ADX)
Number of subjects: 184
Study 29099925 — intervention group
Group type: COMPARATOR
Intervention: Mineralocorticoid receptor antagonists (MRAs)
Number of subjects: 184
Study 27477896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cx601 (120 million cells)
Number of subjects: 212
Study 27477896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24 mL saline solution)
Number of subjects: 212
Study 25900782 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Video Visits (VV)
Number of subjects: 55
Study 25900782 — intervention group
Group type: COMPARATOR
Intervention: Office Visits (OV)
Number of subjects: 55
Study 23713304 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Jiaji (EX‐B 2) points combined with needling local myofascial trigger points (MTrP)
Number of subjects: 66
Study 23713304 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine injection at trigger points
Number of subjects: 66
Study 20979574 — intervention group
Group type: EXPERIMENTAL
Intervention: HFE genotyping offered to participants
Number of subjects: 221
Study 20979574 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on HFE‐HH provided to participants
Number of subjects: 221
Study 20979574 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of signs and symptoms of hemochromatosis
Number of subjects: 221
Study 18814407 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 0
Study 18814407 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 0
Study 18814407 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Simvastatin (universal use)
Number of subjects: 0
Study 18814407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol/sitosterol products (whole population consumption)
Number of subjects: 0
Study 18814407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mmol/L reduction in total cholesterol
Number of subjects: 0
Study 18814407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mmol/L reduction in total cholesterol
Number of subjects: 0
Study 18814407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mmol/L reduction in total cholesterol
Number of subjects: 0
Study 18814407 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mmol/L reduction in total cholesterol
Number of subjects: 0
Study 16800101 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic abacavir (Ranbaxy‐Abacavir)
Number of subjects: 80
Study 14710099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage (McDonald cerclage suture)
Number of subjects: 150
Study 11147929 — intervention group
Group type: EXPERIMENTAL
Intervention: G(‐463)A polymorphism of myeloperoxidase (MPO) gene
Number of subjects: 108
Study 11147929 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific genotypes of cytochrome P4502D6
Number of subjects: 108
Study 11147929 — intervention group
Group type: COMPARATOR
Intervention: Statistical analysis of genetic determinants
Number of subjects: 108
Study 8629631 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 10
Study 8629631 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 10
Study 1464895 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg
Number of subjects: 24
Study 1464895 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg
Number of subjects: 24
Study 1464895 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 8 mg
Number of subjects: 24
Study 1464895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1464895 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2, 4, 8 mg)
Number of subjects: 24
Study 31403812 — intervention group
Group type: EXPERIMENTAL
Intervention: Only the husband received support from the wife
Number of subjects: 98
Study 31403812 — intervention group
Group type: EXPERIMENTAL
Intervention: Only the wife received support from the husband
Number of subjects: 98
Study 31403812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both received support
Number of subjects: 98
Study 31403812 — intervention group
Group type: COMPARATOR
Intervention: Neither spouse received support
Number of subjects: 98
Study 28668774 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum lactate level
Number of subjects: 410
Study 28668774 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified SOFA (mSOFA) score
Number of subjects: 410
Study 28668774 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of lactate
Number of subjects: 410
Study 28668774 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial pH
Number of subjects: 410
Study 28668774 — intervention group
Group type: EXPERIMENTAL
Intervention: Early positive blood cultures
Number of subjects: 410
Study 28668774 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat lactate ≥ 5 mmol/L
Number of subjects: 410
Study 28668774 — intervention group
Group type: EXPERIMENTAL
Intervention: mSOFA score
Number of subjects: 410
Study 26891150 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin (100, 200, or 300 ml based on preoperative serum albumin level)
Number of subjects: 220
Study 26891150 — intervention group
Group type: COMPARATOR
Intervention: Control group (equal volume of saline)
Number of subjects: 220
Study 25397358 — intervention group
Group type: EXPERIMENTAL
Intervention: Serostatus disclosure
Number of subjects: 242
Study 25397358 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who have sex with men (MSM)
Number of subjects: 242
Study 25397358 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 242
Study 22860502 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane safety cannulae at -10 degrees C, 21 degrees C, and 40 degrees C
Number of subjects: 0
Study 22860502 — intervention group
Group type: COMPARATOR
Intervention: Teflon safety cannulae at -10 degrees C, 21 degrees C, and 40 degrees C
Number of subjects: 0
Study 19653067 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal calorie Red Bull
Number of subjects: 68
Study 19653067 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie Red Bull
Number of subjects: 68
Study 19653067 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull consumption
Number of subjects: 68
Study 19653067 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull consumption during cold pressor test (CPT)
Number of subjects: 68
Study 19653067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal calorie and low calorie)
Number of subjects: 68
Study 17625023 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health promotion campaign and contracted healthcare services; includes health education, training of health workers, and subsidized access to pregnancy-related healthcare services at non-public health centres.
Number of subjects: 464
Study 17625023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention); villages serving as controls for comparison.
Number of subjects: 464
Study 16354520 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone ring length of 62 mm (group A)
Number of subjects: 80
Study 16354520 — intervention group
Group type: COMPARATOR
Intervention: Silicone ring length of 77 mm (group B)
Number of subjects: 80
Study 16354520 — intervention group
Group type: EXPERIMENTAL
Intervention: LES hypotonia (mean respiratory pressure <14 mmHg)
Number of subjects: 80
Study 12383062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 4
Study 12383062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 4
Study 12383062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 10216905 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered red-cell packs
Number of subjects: 72